Download PDF
Horm Metab Res 2005; 37(5): 316-325
DOI: 10.1055/s-2005-861487
Original Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Soy Protein Influences the Development of the Metabolic Syndrome in Male Obese ZDFxSHHF Rats

J.  Davis1, 2 , M.  J.  Iqbal1 , J.  Steinle2 , J.  Oitker2 , D.  A.  Higginbotham1, 2 , R.  G.  Peterson3 , W.  J.  Banz1, 2
  • 1 Department of Animal Science, Food & Nutrition, Southern Illinois University, Carbondale, IL, USA
  • 2 Department of Physiology, Southern Illinois University, Carbondale, IL, USA
  • 3 Indiana University School of Medicine, Indianapolis, IN, USA
Further Information

Publication History

Received 18 October 2004

Accepted after revision 20 December 2004

Publication Date:
22 June 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Previous investigations have demonstrated a marked effect of soy protein on the metabolic syndrome (MS). The purpose of this preliminary study was to identify the effects of soy-based diets on male obese ZDFxSHHF (fa/fa-cp/?) rats. Animals were randomly assigned to one of four diets: control, casein (C); low-isoflavone (LIS) soy protein; high-isoflavone (HIS) soy protein; or casein + rosiglitazone (CR). Physiological, biochemical, and molecular parameters were determined at sacrifice. Body weight (p < 0.01) and food intake (p < 0.05) were lower in LIS-fed rodents. Rosiglitazone-treated animals had higher body weight and adiposity (p < 0.05). LIS and CR groups exhibited better glycemic control (p < 0.05), but with a limited effect in rosiglitazone-treated animals. HIS fed rats had higher glucose and triacylglyceride levels (p < 0.01), and lower plasma insulin (p < 0.01). Renal function parameters with the exception of an increase in systolic blood pressure (p < 0.05) were all suppressed in the LIS group (p < 0.01). The CR group had twofold PPARα and PPARγ mRNA abundance (p < 0.01). LIS-fed animals also exhibited greater abundance of PPARγ mRNA (p < 0.001), and nearly threefold FAS and CPT-1 mRNA levels (p < 0.05). HIS-fed rats also had higher abundance of CPT-1 mRNA, as well as a lower abundance of ACC mRNA (p < 0.05). Soy-based diets, influenced by isoflavone content and distinct from rosiglitazone, improved several metabolic parameters in obese ZDFxSHHF rats.

Key words

Soy protein - Isoflavone content - Metabolic syndrome - Gene expression - ZDFxSHHF

References

  • 1 Cefalu W T. Insulin resistance: cellular and clinical concepts.  Experimental Biology and Metabolism. 2001;  226 13-26
    PubMedGoogle Scholar
  • 2 Reaven G M. Pathophysiology of insulin resistance in human disease.  Physiological Reviews. 1995;  75 473-485
    PubMedGoogle Scholar
  • 3 Kaplan N M. The deadly quartet.  Arch Intern Med. 1989;  149 1514-1520
    CrossrefPubMedGoogle Scholar
  • 4 Reaven G M. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
    CrossrefPubMedGoogle Scholar
  • 5 Berger J, Moller D E. The mechanisms of action of PPARs.  Annu Rev Med. 2002;  53 409-435
    CrossrefPubMedGoogle Scholar
  • 6 Ricote M, Huang J T, Welch J S, Glass C K. The peroxisome proliferators-activated receptor-γ (PPARγ) as a regulator of monocyte/macrophage function.  J Leukoc Biol. 1999;  66 733-739
    PubMedGoogle Scholar
  • 7 Keller J M, Collet P, Bianchi A, Huin C, Bouillaud-Kremarik P, Becuwe P, Schohn H, Domenjoud L, Dauca M. Implications of peroxisome proliferators-activatedreceptors (PPARS) in development, cell life status, and disease.  Int J Dev Biol. 2000;  44 429-442
    PubMedGoogle Scholar
  • 8 Willson T M, Lambert M H, Kilewer S A. Peroxisome proliferator-activated receptor-γ and metabolic disease.  Annu Rev Biochem. 2001;  70 341-367
    CrossrefPubMedGoogle Scholar
  • 9 Emilsson V, O'Dowd J, Wang S, Liu Y L, Sennitt M, Heyman R, Cawthorne M A. The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.  Metabolism. 2000;  49 1610-1615
    CrossrefPubMedGoogle Scholar
  • 10 Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49 653) in human adipocytes.  Biochemical and Biophysical Research Communications. 1999;  265 265-271
    CrossrefPubMedGoogle Scholar
  • 11 Smith S A, Lister C A, Toseland C DN, Buckingham R E. Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker Diabetic Fatty rat.  Diabetes, Obesity and Metabolism. 2000;  2 363-372
    CrossrefPubMedGoogle Scholar
  • 12 Ishizuka T, Itaya S, Wada H, Ishizawa M, Kimura M, Kajita K, Kanoh Y, Miura A, Muto N, Yasuda K. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.  Diabetes. 1998;  47 1494-1500
    PubMedGoogle Scholar
  • 13 Brown K K, Henke B R, Blanchard S G, Cobb J E, Mook R, Kaldor I, Kliewer S A, Lehmann J M, Lenhard J M, Harrington W W, Novak P J, Faison W, Binz J G, Hashim M A, Oliver W O, Brown H R, Parks D J, Plunket K D, Tong W Q, Menius J A, Adkison K, Noble S A, Willson T M. A novel n-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker Diabetic Fatty rat.  Diabetes. 1999;  48 1415-1424
    PubMedGoogle Scholar
  • 14 Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.  J Clin Invest. 1998;  101 1354-1351
    CrossrefPubMedGoogle Scholar
  • 15 Kausch C, Krutzfeldt J, Witke A, Rettig A, Bachmann O, Rett K, Matthaei S, Machicao F, Haring H U, Stumvoll M. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.  Biochemical and Biophysical Research Communications. 2001;  280 664-674
    CrossrefPubMedGoogle Scholar
  • 16 Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, Nakao K. Troglitazone induces GLUT4 translocation in L6 myotubes.  Diabetes. 2001;  50 1093-1101
    CrossrefPubMedGoogle Scholar
  • 17 Vidal-Puig A, Jimenez-Linan M, Lowell B B, Hamann A, Hu E, Spiegelman B, Flier J S, Moller D E. Regulation of PPARγ gene expression by nutrition and obesity in rodents.  J Clin Invest. 1996;  97 2553-2561
    CrossrefPubMedGoogle Scholar
  • 18 Yakubu-Madus F E, Stephens T W, Johnson W T. Lipid lowering explains the insulin sensitivity enhancing effects of a thizolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.  Diabetes, Obesity and Metabolism. 2000;  2 155-163
    CrossrefPubMedGoogle Scholar
  • 19 Smith U, Cogg S. Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes.  FASEB. 2001;  15 215-220
    PubMedGoogle Scholar
  • 20 Zierath J R, Ryder J W, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller D E. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action.  Endocrinology. 1998;  139 5034-5041
    CrossrefPubMedGoogle Scholar
  • 21 Scheen A J. Thiazolidinediones and liver toxicity.  Diabetes Metab. 2001;  27 305-313
    PubMedGoogle Scholar
  • 22 Cheng A Y, Fantus I G. Thiazolidinedione-Induced Congestive Heart Failure.  Ann Pharmacother. 2004;  38 817-820
    CrossrefPubMedGoogle Scholar
  • 23 Setchell K DR. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones.  Am J Clin Nutr.. 1998;  68 (Suppl) 1333S-1346S
    CrossrefPubMedGoogle Scholar
  • 24 Erdman J W, Fordyce E J. Soy products and the human diet.  Am J Clin Nutr. 1989;  49 724-37
    PubMedGoogle Scholar
  • 25 Potter S M, Baum J A, Teng H, Stillman R J, Shay N F, Erdman J W Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal woman.  Am J Clin Nutr. 1998;  68 1375S-1379S
    PubMedGoogle Scholar
  • 26 Anderson J W, Johnstone B M. Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids.  N Eng J Med. 1995;  333 276-282
    CrossrefPubMedGoogle Scholar
  • 27 Baum J A, Teng H, Erdman J W Jr, Weigel R M, Klein B P, Persky V W, Freels S, Surya P, Bakhit R M, Ramos E, Shay N F, Potter S M. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women.  Am J Clin Nutr. 1998;  68 545-551
    PubMedGoogle Scholar
  • 28 Vahouny G V, Adamson I, Chalcarz W, Satchithanandam S, Muesing R, Klurfeld D M, Tepper S A, Sanghvi A, Kritchevsky D. Effects of casein and soy protein on hepatic and serum lipids and lipoprotein lipid distribution in the rat.  Atherosclerosis. 1985;  56 127-137
    PubMedGoogle Scholar
  • 29 Anthony M S, Clarkson T B, Williams K J. Effects of soy isoflavones on atherosclerosis: potential mechanisms.  Am J Clin Nutr.. 1998;  68 1390S-1393S
    PubMedGoogle Scholar
  • 30 Anthony M S, Clarkson T B, Bullock B C, Wagner J D. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus mokeys.  Atherosclerosis, Thrombosis, and Vascular Biology. 1997;  17 2524-2531
    PubMedGoogle Scholar
  • 31 Maddox D A, Alavi F K, Silbernick E M, Zawada E T. Protective effects of a soy diet in preventing obesity-linked renal disease.  Kidney International. 2002;  61 96-104
    CrossrefPubMedGoogle Scholar
  • 32 Peluso M R, Winters T A, Shanahan M F, Banz W J. A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats.  J Nutr. 2000;  130 2333-2342
    PubMedGoogle Scholar
  • 33 Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats.  Endocrinology and Metabolism. 2000;  278 E491-E500
    PubMedGoogle Scholar
  • 34 Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H. Dietary soybean protein increases insulin receptor gene expression in Wistar Fatty rats when dietary polyunsaturated fatty acid level is low.  J Nutr. 1997;  127 1077-1083
    PubMedGoogle Scholar
  • 35 Tovar-Palacio C, Potter S M, Hafermann J C, Shay N F. Intake of soy protein and soy protein extracts influencelipid metabolism and hepatic gene expression in gerbils.  J Nutr. 1998;  128 839-842
    PubMedGoogle Scholar
  • 36 Dixon R A, Ferreira D. Genistein.  Phytochemistry.. 2002;  60 205-211
    CrossrefPubMedGoogle Scholar
  • 37 Crouse J R 3rd, Morgan T, Terry J G, Ellis J, Vitolins M, Burke G L. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins.  Arch Intern Med. 1999;  159 2070-2076
    CrossrefPubMedGoogle Scholar
  • 38 Sanders T A, Dean T S, Grainger D, Miller G J, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor β 1 concentrations and hemostatic risk factors for coronary heart disease in healthy subjects.  Am J Clin Nutr. 2002;  76 373-377
    PubMedGoogle Scholar
  • 39 Fukui K, Tachibana N, Wanezaki S, Tsuzaki S, Takamatsu K, Yamamoto T, Hashimoto Y, Shimoda T. Isoflavone-free soy protein prepared by column chromatography reduces plasma cholesterol in rats.  J Agric Food Chem. 2002;  50 5717-5721
    CrossrefPubMedGoogle Scholar
  • 40 Jenkins D J, Kendall C W, Jackson C J, Connelly P W, Parker T, Faulkner D, Vidgen E, Cunnane S C, Leiter L A, Josse R G. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women.  Am J Clin Nutr. 2002;  76 365-372
    PubMedGoogle Scholar
  • 41 Dang Z C, Audinot V, Papapoulos S E, Boutin J A, Lowik C W. PPARγ as a molecular target for the soy phytoestrogen genistein.  J Biol Chem. 2003;  278 962-967
    CrossrefPubMedGoogle Scholar
  • 42 Harmon A W, Harp J B. Differential effects of flavonoids on 3T3-L1 adipogenesis and lipolysis.  Am J Physio. 2001;  280 C807-C813
    PubMedGoogle Scholar
  • 43 Mezei O, Banz W J, Steger R W, Peluso M R, Winters T A, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264. 7 cells.  J Nutr. 2003;  133 1238-1243
    PubMedGoogle Scholar
  • 44 Tofovic S P, Kusaka H, Kost C K Jr, Bastacky S. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats.  Ren Fail. 2000;  22 387-406
    CrossrefPubMedGoogle Scholar
  • 45 Reeves P G, Nielsen F H, Fahey G C Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet.  J Nutr. 1993;  123 1939-1951
    PubMedGoogle Scholar
  • 46 Folch J, Lees M, Sloane-Stanley G H. A simple method for the isolation and purification of total lipids from animal tissues.  J Biol Chem. 1957;  226 497-509
    PubMedGoogle Scholar
  • 47 Fletcher M J. A colorimetric method for estimating serum triglycerides.  Clin Chem. 1968;  22 393-397
    CrossrefPubMedGoogle Scholar
  • 48 Harris R B, Martin R J. Specific depletion of body fat in parabiotic partners of tube-fed obese rats.  Am J Physiol. 1984;  247 R380-R386
    PubMedGoogle Scholar
  • 49 Livak K J, Schmittgen T D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔCT Method.  Methods. 2001;  25 402-408
    CrossrefPubMedGoogle Scholar
  • 50 Tomanek R J, Palmer P J, Peiffer G L, Schreiber K L, Eastham C L, Marcus M L. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ.  Res. 1986;  58 38-46
    PubMedGoogle Scholar
  • 51 Cimini C M, Weiss H R. Microvascular morphometry and perfusion in renal hypertension-induced cardiac hypertrophy. Am.  J Physiol. 1988;  255 H1384-H1390
    PubMedGoogle Scholar
  • 52 Nevala R, Vaskonen T, Vehniainen J, Korpela R, Vapaatalo H. Soy based diet attenuates the development of hypertension when compared to casein based diet in spontaneously hypertensive rat.  Life Sci. 2000;  66 115-124
    PubMedGoogle Scholar
  • 53 Iqbal M J, Yaegashi S, Ahsan R, Lightfoot D A, Banz W J. Differentially abundant mRNAs in rat liver in response to diets containing soy protein isolate.  Physiol Genomics. 2002;  11 219-226
    PubMedGoogle Scholar
  • 54 Davis J, Higginbotham A, Iqbal J, Peterson R, Shay N, Banz W. Soy protein diets attenuate abnormalities observed in male ZDF rats. 2003 Experimental Biology meeting abstracts [accessed at http://select. biosis. org/faseb].  The FASEB Journal. 18;  Abstract #197. 2
    PubMedGoogle Scholar
  • 55 Nagasawa A, Fukui K, Funahashi T, Maeda N, Shimomura I, Kihara S, Waki M, Takamatsu K, Matsuzawa Y. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin.  Horm Metab Res. 2002;  34 635-639
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Bartke A, Peluso M R, Moretz N, Wright C, Bonkowski M, Winters T A, Shanahan M F, Kopchick J J, Banz W J. Effects of Soy-derived diets on plasma and liver lipids, glucose tolerance, and longevity in normal, long-lived and short-lived mice.  Horm Metab Res. 2004;  36 550-558
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Banz W J, Davis J, Peterson R, Iqbal M J. Gene expression and adiposity are modified by soy protein in male Zucker diabetic fatty rats.  Obes Res. 2004;  12 1907-1913
    PubMedGoogle Scholar
  • 58 Chakrabarti R, Misra P, Vikramadithyan R K, Premkumar M, Hiriyan J, Datla S R, Damarla R K, Suresh J, Rajagopalan R. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma.  Eur J Pharmacol. 2004;  3 195-206
    PubMedGoogle Scholar
  • 59 Brand C L, Sturis J, Gotfredsen C F, Fleckner J, Fledelius C, Hansen B F, Andersen B, Ye J M, Sauerberg P, Wassermann K. Dual PPAR alpha/ gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.  Am J Physiol Endocrinol Metab. 2003;  284 E841-E854
    PubMedGoogle Scholar

William J. Banz, Ph. D., RD

Department of Animal Science, Food and Nutrition

Southern Illinois University · Carbondale · IL 62901-4317 · USA

Phone: +1 (618) 453 75 11

Fax: +1 (618) 453-75 17

Email: banz@siu.edu

      >